DYN240920C50000
- 0.08
- -1.23-93.89%
Dyne Therapeutics Newsroom
Express News | Dyne Therapeutics Announces New Clinical Data From Phase 1/2 Deliver Trial of Dyne-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts
Chardan Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $50
Buy Rating Affirmed Amidst Dose Adjustments and Promising Trial Results for Dyne Therapeutics
Small U.S. Stocks Decrease; Dyne Therapeutics Takes Biggest Hit
Dyne Therapeutics Analyst Ratings
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
Oppenheimer Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
Stifel Maintains Dyne Therapeutics(DYN.US) With Buy Rating
Vaxcyte PCVX Phase 1/2 Data; Dyne Therapeutics DYN Phase 1/2 DMD Results
Express News | Dyne Therapeutics Shares Down 29.5% Premarket After Co Reports Early-Mid-Stage Study Data for Muscular Disorder Drug
Express News | Dyne Therapeutics Inc - Dyne-251 Demonstrates Favorable Safety Profile
Press Release: Dyne Therapeutics Announces Key Leadership Appointments
Express News | Dyne Therapeutics Inc - Initiating Registrational Cohorts With Update on Path to Registration by Year-End 2024
Express News | Dyne Therapeutics Inc - to Provide Registration Update by Year-End
Dyne Therapeutics Announces New Clinical Data From Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts
Dyne Therapeutics(DYN.US) Director Sells US$6.05 Million in Common Stock
Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Dyne Therapeutics(DYN.US) Director Sells US$6.95 Million in Common Stock
Dyne Therapeutics(DYN.US) Director Sells US$8.3 Million in Common Stock
Dyne Therapeutics(DYN.US) Director Sells US$10.38 Million in Common Stock